Press Releases

2023 Hearst Health Prize - AI for Incidental CAC

Congratulations to Stanford Medicine on winning the 2023 Hearst Health Prize for its artificial intelligence solution that helps identify patients at risk for heart attack by scoring incidental coronary artery calcium (CAC) on non-gated chest CTs.

DASI Simulations' PrecisionTAVI gets CMS Hospital Outpatient Billing Code

Predictive model generation for pre-planning a cardiac procedure now reimbursable by Medicare at approximately $1,000 per model

Echo IQ's breakthrough research on cardiovascular health continues with unveiling of AI-driven aortic stenosis and mitral regurgitation detection results at ESC 2023 Congress

Late-Breaking Science sessions reveal revolutionary findings on severe aortic stenosis and mild-to-severe mitral regurgitation identification through innovative AI technology.

Keystone Perfusion Services, PC recognized for life-saving contribution during COVID-19 pandemic, secures fifth consecutive year on Inc. 5000 list

Aug 15, 2023 | Submitted by: Keystone Perfusion Services, PC

The company's multifaceted healthcare staffing solutions play a pivotal role in transforming patient care and elevating industry standards.

Corazon and the Society for Cardiovascular Angiography and Interventions announce partnership

The agreement formally endorses Corazon’s cardiovascular accreditation.

Arineta announces SpotLight Duo, the world’s first dedicated cardiovascular and thoracic CT system

Arineta Cardio Imaging is excited to announce the FDA 510(k) clearance of the SpotLight and SpotLight Duo family of cardiovascular CT scanners.

Study Confirms Ultromics’ AI Can Improve HFpEF Detection Using a Single Echocardiogram View

Researchers and engineers at Mayo Clinic and Ultromics developed technology that can detect HFpEF using a single A4C echocardiogram clip, to help clinicians detect a complex form of heart failure easily and accurately.

Cassling connects cardiologists with revolutionary AI software

The Midwest company will begin offering EchoSolv, an artificial intelligence clinical decision support platform designed to help detect severe aortic stenosis, to providers throughout the country.

DASI Simulation’s Precision TAVI earns FDA clearance

Jun 14, 2023 | Submitted by: DASI Simulations

Precision TAVI is the first FDA-approved predictive modeling tool for medical teams planning TAVR procedures.

RecoverRite®, American College of Cardiology Collaborate to Change the Face of Cardiovascular Patient Education

RecoverRite’s Online Heart Learning Center to feature ACC’s CardioSmart patient tools and resources.

Study shows PulseAI’s deep learning algorithm outperforms the Apple Watch ECG algorithm in detecting atrial fibrillation

PulseAI, a leader in the development of cutting-edge AI-powered ECG software, has released the results of a clinical study that has shown the superiority of its deep learning AI over the Apple Watch ECG algorithm in the detection of atrial fibrillation.

$20M gift announced by the Rooney Foundation in support of enhanced cardiac care at NCH

NAPLES, Fla. – February 20, 2023 The NCH Healthcare System is proud to announce a $20 million naming gift from the Rooney Foundation, which is the philanthropic arm of the former U.S. Representative for Florida's 19th congressional district and his wife, Francis and Kathleen Rooney. In recognition of increasing their $8 million pledge announced last July, the entire cardiac program across NCH Healthcare System will be renamed “The Rooney Heart Institute.”

NCH announces second historic gift in as many weeks totaling a record $40M in support of enhanced care

NAPLES, Fla. – February 21, 2023 On the heels of our historic $20 Million gift announcement made last week, NCH is proud to announce yet a second $20 million naming gift in as many weeks from Diana and Don Wingard. This generous gift will provide the necessary funds to ensure that the NCH Stroke program continues to provide the highest level of care and treatment to patients in Southwest Florida. Additionally, in recognition of the extraordinary pledge, the entire stroke program across NCH will be renamed the “Wingard Stroke Institute.”

Patient Image Exchange puts patients 'in the driver’s seat'

When using this service, patients have the ability to upload and share data without limitations. From radiology CDs to PDFs or JPG files, patients can use their smartphone connected to the Patient Image Exchange app and upload images, share lab results, immunizations records, nurses’ notes, dental images and much more.

Ancora Heart appoints David J. Tucker as chief financial officer

Ancora Heart has hired senior financial leader David J. Tucker as its chief financial officer. This is the company's second C-suite hire in 2022, following the addition of Mark Miles as chief commercial officer in June.

Geneticure presents data successfully identifying responders and non-responders to renal denervation using genetic screening

Geneticure, a global leader in the genetic variability of response to hypertension treatments, presented data at the 2022 American Heart Association Scientific Sessions meeting from a recent clinical study in which they were able to successfully predict patients who will respond to renal denervation (RDN). In addition, the Geneticure test for renal denervation also identified patients with an increase in blood pressure, following the procedure.

Cardiac Insight Comments on CMS Announcement of National Payment Rates for Long-Term Continuous ECG (LT-ECG) Monitoring in 2023

Long-awaited milestone gives physicians and their patients greater access to prescription cardiac arrhythmia detection solutions, including the company’s Cardea SOLO™ ECG System

Siemens Healthineers launches next generation of cardiovascular imaging and information solution, syngo Dynamics, at ACC 2018

At the American College of Cardiology’s 67th Annual Scientific Session and Expo, Siemens Healthineers has launched the next generation of syngo Dynamics, a cardiovascular imaging and information solution. The newest version of the software emphasizes enhanced security, widespread access, enterprise consistency, and structured reporting.

Boehringer Ingelheim and Lilly expand heart failure program for Jardiance® with new exercise capacity trials

RIDGEFIELD, Conn. and INDIANAPOLIS, March 6, 2018 /PRNewswire/ — Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced plans to expand their clinical trial program for Jardiance® in chronic heart failure with the EMPERIAL clinical trials.

HeartFlow Enters into Licensing Agreement with Cedars-Sinai for Coronary Plaque Assessment Technology

REDWOOD CITY, Calif., March 1, 2018 — HeartFlow, Inc. today announced that it has entered into a licensing and technology transfer agreement with Cedars-Sinai in Los Angeles for AutoPlaque technology, a software tool used to detect and characterize coronary artery plaque based on coronary computed tomography angiography (CCTA) images.

First Longeveron Mesenchymal Stem Cell Treatment Administered to an Infant with Rare Heart Condition as Part of Groundbreaking Clinical Trial

MIAMI, Feb. 27, 2018 — Longeveron announced that its pioneering clinical trial to treat infants with Hypoplastic Left Heart Syndrome officially started with the first patient receiving the company's mesenchymal stem cell therapy in a procedure performed at the University of Maryland Medical Center in Baltimore.

Medtronic Receives FDA Approval for New Arm Indication for Guardian(TM) Sensor 3

DUBLIN — February 26, 2018 — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that the U.S. Food and Drug Administration (FDA) has approved a new arm indication for the Guardian(TM) Sensor 3.

New Data Show Lilly's Trulicity® (dulaglutide) in Combination with an SGLT-2 Inhibitor Improves Blood Sugar Control in People with Type 2 Diabetes

INDIANAPOLIS, Feb. 26, 2018 — Trulicity® (dulaglutide) significantly improves A1C (average blood sugar concentration over two to three months) when added to ongoing treatment with a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, according to results from AWARD-10, a new Phase 3b clinical study. These data were published online first in The Lancet Diabetes & Endocrinology.

Medtronic Reports Third Quarter Financial Results

DUBLIN — February 20, 2018 — Medtronic plc (NYSE: MDT) today announced financial results for its third quarter of fiscal year 2018, which ended January 26, 2018.

Cardiva Medical Brings Total Financing Round to $41 Million; Announces Sponsorship of AMBULATE Trial

SANTA CLARA, Calif.—February 20, 2018—Cardiva Medical®, an innovator in the field of vascular closure, today announced that the company has closed on $11 million in additional financing — bringing total equity and debt financing in the current round to $41 million.

New Pediatric At-Home Study of MiniMed(TM) 670G System Demonstrates Positive Results in Children Ages 7 to 13

DUBLIN and VIENNA — February 15, 2018 — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that new data from its at-home pediatric study of the MiniMed(TM) 670G system in patients 7-13 years of age were presented at the Advanced Technologies & Treatments for Diabetes (ATTD) 11th International Conference in Vienna, Austria. 

DreaMed Diabetes Receives CE Mark for Platform for the Management of Type 1 Diabetes

PETAH TIKVA, Israel, February 15, 2018 — DreaMed Diabetes, developer of diabetes management solutions, announced today that it received CE Mark for the Advisor Pro decision-support platform for assisting healthcare professionals in the management of Type 1 diabetes.

HeartFlow Completes Series E Financing, Securing $240 Million

REDWOOD CITY, Calif.—HeartFlow, Inc. today announced the closing of its Series E financing, securing $240 million. The company will use the proceeds from this financing to ramp up commercial expansion of the HeartFlow® FFRct Analysis, continued technology innovation and additional clinical studies.

Abiomed Announces Peripartum and Postpartum Cardiomyopathy Approval and Women's Initiative for Heart Recovery

DANVERS, Mass., Feb. 13, 2018 (GLOBE NEWSWIRE) — Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced today the launch of a new indication and Women's Initiative focused on heart recovery education and awareness.

Terumo announces £33m investment in Scottish medical device factory

Tokyo-based Terumo Corporation has today announced an investment of £33 million in one of its subsidiary companies, Vascutek Limited, located near Glasgow.

American College of Cardiology Expands Patient Navigator Program

Hundreds of hospitals across the United States will have access to tools and resources to help improve care and lower readmission rates for myocardial infarction (MI) patients as part of the American College of Cardiology’s expanded Patient Navigator Program: Focus MI Quality Campaign.

Acesion Pharma Receives Approval for Phase I Study in Atrial Fibrillation

COPENHAGEN, February 8, 2018 — Acesion Pharma ("Acesion" or the Company), a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia, announces today it has received approval to commence its first clinical study for its lead compound AP30663. The phase 1 study in healthy subjects will be conducted at the Centre for Human Drug Research (CHDR) in the Netherlands and is due to start in March 2018.

New Doctors Report Illness Tracker Ranks Nation’s Top Flu Hot Spots

Pittsburgh, PA, February 7, 2018 — DoctorsReport.com, the new Website and mobile app that give you instant access to data doctors report from almost one million doctors’ offices across the nation, has released its current list of the nation’s 14 Influenza hot spots (by metro area) in the country.

Health AI Startup Medial EarlySign Predicts Which Diabetic Patients Will Suffer Kidney Damage Within One Year

KFAR MALAL, Israel, Feb. 5, 2018 — Medial EarlySign, a leader of machine-learning based solutions to improve non-communicable disease management, today announced the results of an additional clinical data study in the domain of diabetes — identifying diabetic patients who are at highest risk for having renal dysfunction within one year.

IN.PACT Admiral Demonstrates Consistent and Durable Outcomes in New Two-Year Japan Data and IN.PACT Global Critical Limb Ischemia Cohort Analysis

DUBLIN and LEIPZIG — January 30, 2018 — Medtronic plc (NYSE: MDT) today added to its robust body of clinical evidence supporting the IN.PACT(TM) Admiral(TM) drug-coated balloon (DCB) with new presentations that demonstrated durable and consistent clinical outcomes in peripheral artery disease (PAD).

Medtronic Launches IDE Study to Evaluate the Abre(TM) Venous Self-Expanding Stent System in Patients with Deep Venous Disease

DUBLIN — January 26, 2018 — Medtronic plc (NYSE: MDT) today announced the initiation of its investigational device exemption (IDE) study for the Abre(TM) venous self-expanding stent system. The ABRE IDE Study will evaluate the safety and effectiveness of the Abre stent in subjects with iliofemoral venous outflow obstruction.

Medtronic Launches ENCHANT Study to Evaluate ChEVAR Parallel Graft Technique with the Endurant(TM) II/IIs Stent Graft System

DUBLIN — January 24, 2018 — Medtronic plc (NYSE: MDT) today announced the launch of the ENCHANT (ENdurantCHEVAR New Indication Trial) study. The post-market, non-interventional, multi-center, non-randomized, single-arm study will enroll approximately 150 patients across 25 sites in Europe and Russia, and will evaluate the safety and performance of a ChEVAR procedure using the Endurant(TM) II/IIs stent graft system in a real-world setting.

Noted Cardiologists Jennifer H. Mieres, MD and Stacey E. Rosen, MD Launch Call to Action and New Book "Heart Smart For Women: Six S.T.E.P.S. in Six Weeks To Heart-Healthy Living"

NEW YORK, Jan. 22, 2018 — Noted cardiologists, Jennifer H. Mieres, MD, and Stacey E. Rosen, MD, launch Heart Smart For Women; Six S.T.E.P.S. in Six Weeks To Heart- Healthy Living; a new book that demystifies the science, biology and statistics surrounding heart disease while providing a user-friendly program for successful heart-healthy living.